NCT00387257View on ClinicalTrials.gov

Effect Of Rilapladib (SB-659032) On Platelet Aggregation

PHASE1CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Healthy SubjectsAtherosclerosis

Interventions

DRUG

Rilapladib (SB-659032)

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY